Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 6/2017

01-12-2017 | Research Article

Preventive effect of pre-warming, hot compress, and pH adjustment in oxaliplatin-induced venous pain

Authors: Hitoshi Kawazoe, Satomi Sumikawa, Kana Nakauchi, Yoshihiro Yakushijin, Yuji Yamamoto, Yuji Watanabe, Akihiro Tanaka, Hiroaki Araki

Published in: International Journal of Clinical Pharmacy | Issue 6/2017

Login to get access

Abstract

Background Venous pain induced by peripheral intravenous administration of oxaliplatin remains clinically unresolved. Objective The aim of this study was to determine the efficacy of comprehensive intervention care for venous pain in colorectal cancer patients receiving oxaliplatin. Setting A Japanese tertiary hospital. Method We treated all outpatients after April 2012 with comprehensive intervention care including pre-warming of the oxaliplatin solution, use of a hot compress, and pH adjustment by combination with dexamethasone. We retrospectively reviewed the electronic medical records from colorectal cancer patients who had received oxaliplatin via a peripheral vein between December 2009 and June 2014. Main outcome measures The primary endpoint of this study was the incidence of venous pain at the administration site during oxaliplatin infusion, according to injection site reaction grade ≥ 2. Results We evaluated 271 treatment courses in 59 patients. Venous pain occurred in 42 courses (15.5%) among 26 patients. Multivariate logistic regression analysis revealed that female gender and body mass index ≥ 25 kg/m2 were significantly associated with an increased risk of venous pain during all courses (adjusted odds ratio [OR]: 3.18, 95% confidence interval [CI] 1.35–7.92; P < 0.01; and adjusted OR: 3.37, 95% CI 1.26–9.40; P = 0.02, respectively), whereas comprehensive intervention care were significantly associated with reduced risk of venous pain during all courses (adjusted OR: 0.10, 95% CI 0.02–0.44; P < 0.01). Conclusion Comprehensive intervention care is a clinical treatment option for oxaliplatin-induced peripheral venous pain in patients with colorectal cancer, especially females with obesity.
Literature
1.
go back to reference de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938–47.CrossRefPubMed de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938–47.CrossRefPubMed
2.
go back to reference Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23–30.CrossRefPubMed Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23–30.CrossRefPubMed
3.
go back to reference Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008;26:2006–12.CrossRefPubMed Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008;26:2006–12.CrossRefPubMed
4.
go back to reference Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013–9.CrossRefPubMed Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013–9.CrossRefPubMed
5.
go back to reference Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29:1465–71.CrossRefPubMed Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29:1465–71.CrossRefPubMed
6.
go back to reference Yamada Y, Takahari D, Matsumoto H, Baba H, Nakamura M, Yoshida K, et al. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol. 2013;14:1278–86.CrossRefPubMed Yamada Y, Takahari D, Matsumoto H, Baba H, Nakamura M, Yoshida K, et al. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol. 2013;14:1278–86.CrossRefPubMed
7.
go back to reference Yoshida Y, Hoshino S, Aisu N, Naito M, Tanimura S, Mogi A, et al. Administration of chemotherapy via the median cubital vein without implantable central venous access ports: port-free chemotherapy for metastatic colorectal cancer patients. Int J Clin Oncol. 2015;20:332–7.CrossRefPubMed Yoshida Y, Hoshino S, Aisu N, Naito M, Tanimura S, Mogi A, et al. Administration of chemotherapy via the median cubital vein without implantable central venous access ports: port-free chemotherapy for metastatic colorectal cancer patients. Int J Clin Oncol. 2015;20:332–7.CrossRefPubMed
8.
go back to reference Matsuyama K, Mishima H, Ueno H, Kajihara K, Morioka A, Morimoto S, et al. Etiology and management of venous pain during intravenous administration of oxaliplatin. Gan To Kagaku Ryoho. 2011;38:411–4 (in Japanese).PubMed Matsuyama K, Mishima H, Ueno H, Kajihara K, Morioka A, Morimoto S, et al. Etiology and management of venous pain during intravenous administration of oxaliplatin. Gan To Kagaku Ryoho. 2011;38:411–4 (in Japanese).PubMed
9.
go back to reference Yoshida Y, Hoshino S, Aisu N, Shiwaku H, Beppu R, Tanimura S, et al. Dexamethasone as a means not only for controlling vascular pain caused by the administration of oxaliplatin via the peripheral vein but also for controlling oxaliplatin-induced hypersensitivity reactions. Br J Med Med Res. 2012;2:132–41.CrossRef Yoshida Y, Hoshino S, Aisu N, Shiwaku H, Beppu R, Tanimura S, et al. Dexamethasone as a means not only for controlling vascular pain caused by the administration of oxaliplatin via the peripheral vein but also for controlling oxaliplatin-induced hypersensitivity reactions. Br J Med Med Res. 2012;2:132–41.CrossRef
10.
go back to reference Miyajima R, Kawazoe H, Tsuneoka K, Fujiwara M, Kojima Y, Yakushijin Y. Preventive trial of preheating administration of oxaliplatin-diluted solution in combination with a hot compress for oxaliplatin-induced venous pain. Gan To Kagaku Ryoho. 2013;40:537–40 (in Japanese).PubMed Miyajima R, Kawazoe H, Tsuneoka K, Fujiwara M, Kojima Y, Yakushijin Y. Preventive trial of preheating administration of oxaliplatin-diluted solution in combination with a hot compress for oxaliplatin-induced venous pain. Gan To Kagaku Ryoho. 2013;40:537–40 (in Japanese).PubMed
11.
go back to reference Nakauchi K, Kawazoe H, Miyajima R, Waizumi C, Rokkaku Y, Tsuneoka K, et al. Risk factors for oxaliplatin-induced phlebitis and venous pain, and evaluation of the preventive effect of preheating with a hot compress for administration of oxaliplatin. Gan To Kagaku Ryoho. 2015;42:1397–400 (in Japanese).PubMed Nakauchi K, Kawazoe H, Miyajima R, Waizumi C, Rokkaku Y, Tsuneoka K, et al. Risk factors for oxaliplatin-induced phlebitis and venous pain, and evaluation of the preventive effect of preheating with a hot compress for administration of oxaliplatin. Gan To Kagaku Ryoho. 2015;42:1397–400 (in Japanese).PubMed
12.
go back to reference Hata T, Honda M, Kobayashi M, Toyokawa A, Tsuda M, Tokunaga Y, et al. Effect of pH adjustment by mixing steroid for venous pain in colorectal cancer patients receiving oxaliplatin through peripheral vein: a multicenter randomized phase II study (APOLLO). Cancer Chemother Pharmacol. 2015;76:1209–15.CrossRefPubMed Hata T, Honda M, Kobayashi M, Toyokawa A, Tsuda M, Tokunaga Y, et al. Effect of pH adjustment by mixing steroid for venous pain in colorectal cancer patients receiving oxaliplatin through peripheral vein: a multicenter randomized phase II study (APOLLO). Cancer Chemother Pharmacol. 2015;76:1209–15.CrossRefPubMed
14.
go back to reference Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El OA, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002;13:267–72.CrossRefPubMed Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El OA, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002;13:267–72.CrossRefPubMed
15.
go back to reference Royal College of Nursing. Standards for infusion therapy, the RCN IV therapy forum. 3rd ed. London: The Royal College of Nursing; 2010. p. 26–7. Royal College of Nursing. Standards for infusion therapy, the RCN IV therapy forum. 3rd ed. London: The Royal College of Nursing; 2010. p. 26–7.
16.
go back to reference Suga Y, Sakaguchi Y, Ishizaki J, Takabayashi M, Hashimoto C, Hiromasa A, et al. Investigation for risk factor and preventive effect of NSAIDs, opioid on gemcitabine-induced vascular pain. Jpn J Pharm Heath Care Sci. 2012;38:177–83 (in Japanese).CrossRef Suga Y, Sakaguchi Y, Ishizaki J, Takabayashi M, Hashimoto C, Hiromasa A, et al. Investigation for risk factor and preventive effect of NSAIDs, opioid on gemcitabine-induced vascular pain. Jpn J Pharm Heath Care Sci. 2012;38:177–83 (in Japanese).CrossRef
17.
go back to reference Yoh K, Niho S, Goto K, Ohmatsu H, Kubota K, Kakinuma R, et al. High body mass index correlates with increased risk of venous irritation by vinorelbine infusion. Jpn J Clin Oncol. 2004;34:206–9.CrossRefPubMed Yoh K, Niho S, Goto K, Ohmatsu H, Kubota K, Kakinuma R, et al. High body mass index correlates with increased risk of venous irritation by vinorelbine infusion. Jpn J Clin Oncol. 2004;34:206–9.CrossRefPubMed
Metadata
Title
Preventive effect of pre-warming, hot compress, and pH adjustment in oxaliplatin-induced venous pain
Authors
Hitoshi Kawazoe
Satomi Sumikawa
Kana Nakauchi
Yoshihiro Yakushijin
Yuji Yamamoto
Yuji Watanabe
Akihiro Tanaka
Hiroaki Araki
Publication date
01-12-2017
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 6/2017
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-017-0536-1

Other articles of this Issue 6/2017

International Journal of Clinical Pharmacy 6/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.